Adenosine A1 Receptor (ADORA1) Drug Discovery Landscape & Assay Solutions
- By admin
- 03 Jul 2026
- Comments
Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Cardiovascular, Neurological, and Inflammatory Therapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ADORA1 (Adenosine A1 Receptor) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Gene Delivery (GPCR Focus) | ADORA1 Promise-ORF / Lentivirus For stable cell line construction preserving native multi-pass transmembrane conformation. |
View ADORA1 Products |
| Antigen – Membrane Protein | ADORA1 Membrane Protein (HEK293 Overexpression) Full-length GPCR, Native glycosylation, Endotoxin <1EU/ug, Sequence Verified |
View ADORA1 Products |
| Antigen – Detergent Solubilized | ADORA1 Recombinant Protein (Detergent Solubilized) Sequence Verified, High Purity (>95%), Endotoxin <1EU/ug |
View ADORA1 Products |
| Benchmark Ab | Anti-ADORA1 Recombinant Control Sequence Verified binding control for flow cytometry, Endotoxin Controlled |
View ADORA1 Products |
| Validator | ADORA1 siRNA Set For knockdown verification and specificity checks in cell-based assays, Theoretical MW validated |
View ADORA1 Products |
| Related Target A | ADORA2A Critical for counter-screening and subtype selectivity profiling |
View ADORA2A Products |
| Related Target B | ADORA3 Adenosine receptor family member for comprehensive cross-reactivity panels |
View ADORA3 Products |
| Related Target C | CD73 (NT5E) Upstream adenosine generator, synergistic target for adenosine pathway studies |
View NT5E Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GPCR Conformational Integrity | Lentivirus-Based Stable Cell Lines (HEK293 Expressed, Native Membrane Context, High Purity >95% by Flow Cytometry); essential for GPCR native folding |
| Subfamily Selectivity (vs A2A/A2B/A3) | Homolog panel lentivirus and plasmids strictly sequence verified for off-target validation; includes human/mouse/cyno ADORA1 + ADORA2A/ADORA3 |
| Gi/o-coupled Signaling Detection | Pre-configured cAMP Biosensor Cell Lines compatible with ADORA1 lentivirus (theoretical sensitivity <1nM) |
| Species Translation (Human to Preclinical) | Cross-species Lentivirus Library (Human, Mouse, Cynomolgus) with >95% sequence coverage |
| Lack of Positive Controls | Recombinant control antibodies available for assay calibration and flow cytometry standard curves |
| False Positives in Cell Assays | Validating siRNA sets included for rigorous background subtraction and specificity checks |
Live ADORA1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ADORA1 therapeutics is evolving from traditional orthosteric agonists/antagonists—which often suffer from systemic on-target side effects like bradycardia—to highly selective Positive Allosteric Modulators (PAMs). As first-generation small molecules reach clinical checkpoints, the next wave of R&D is targeting biased agonism and tissue-specific modulation to separate therapeutic efficacy (e.g., in pain management, heart failure, and renal fibrosis) from cardiovascular toxicity. Ongoing research also explores ADORA1's role in neuroprotection and inflammation, expanding its therapeutic potential beyond classical indications.
Competitive Modality & Indication Snapshot
| Modality | Representative Focus | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Positive Allosteric Modulators (PAMs) | Small Molecules | Neuropathic Pain, Heart Failure | Cell-Based Functional Assay (Need ADORA1 Lentivirus for stable expression) |
| Orthosteric Antagonists | Small Molecules | Renal Impairment, Diuresis | Selectivity Screening (Need ADORA2A/A3 counter-screens) |
| Biologics / mAbs | Monoclonal Antibodies | Cardiovascular, CNS research | Flow Cytometry Binding (Need Native-conformation stable cell lines) |
Key Genetic Variants
Known missense variants in ADORA1 (e.g., rs11547175, rs11547174, rs11547176) may influence receptor function and drug response. These mutations, documented in UniProt (P30542), serve as important considerations in personalized medicine approaches for ADORA1-targeted therapies.